symptomatic

[키워드] 1:1 24 hour absolute difference acute illness adjusted adjusted relative risk Adverse adverse event age all-cause hospitalization Brazil Canada clinical clinical trial collected conducted COVID-19 COVID-19 progression Critical death diarrhea Disease progression duration of follow-up Effect Efficacy end point evaluate event favor Follow-up high-risk patient Hospitalization increased risk infected with SARS-CoV-2 interim analysis intravenous intravenous dose Latinx management mechanical ventilation median age Mild Moderate COVID-19 neutralizing antibody outcome Patient patients randomized patients with COVID-19 Placebo Pneumonia Prevent Primary outcome progression proportion Randomized reduced requiring supplemental oxygen risk risk factor SARS-CoV-2 variant secondary outcome severe disease significantly Sotrovimab Spain statistically significant Support symptomatic tested the median those with comorbidity Treatment treatment group
[DOI] 10.1001/jama.2022.2832 PMC 바로가기 [Article Type] Randomized Controlled Trial